Biofrontera (NASDAQ:BFRI) Stock Price Down 5.6% – Time to Sell?

Biofrontera Inc. (NASDAQ:BFRI) shares fell 5.6% on Thursday . The stock traded as low as $0.8010 and last traded at $0.8379. 94,857 shares changed hands during trading, a decline of 20% from the average session volume of 118,083 shares. The stock had previously closed at $0.8875.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biofrontera in a research note on Thursday, October 30th. Benchmark restated a “buy” rating on shares of Biofrontera in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.75.

Biofrontera Price Performance

The company’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $0.90. The firm has a market capitalization of $9.56 million, a PE ratio of -0.50 and a beta of 0.62.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.01. Biofrontera had a negative net margin of 47.28% and a negative return on equity of 1,104.09%. The firm had revenue of $6.99 million during the quarter, compared to the consensus estimate of $7.00 million. Analysts forecast that Biofrontera Inc. will post -3.01 earnings per share for the current year.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. AIGH Capital Management LLC grew its holdings in Biofrontera Inc. (NASDAQ:BFRI) by 7.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,046,050 shares of the company’s stock after buying an additional 71,525 shares during the period. AIGH Capital Management LLC owned 10.32% of Biofrontera worth $1,030,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.